{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:17:55Z","timestamp":1790983075526,"version":"4.1.0"},"reference-count":36,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","issue":"spe3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"DOI":"10.31744\/einstein_journal\/2026rc2409","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:57:56Z","timestamp":1787590676000},"source":"Crossref","is-referenced-by-count":1,"title":["Management of oral stomatitis associated with BRAFi-MEKi therapy using intralesional corticosteroid and local anesthetic: a case report"],"prefix":"10.31744","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0169-7546","authenticated-orcid":false,"given":"Maria Cecilia Querido de","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-5629","authenticated-orcid":false,"given":"Maria Cl\u00e1udia","family":"Cuzzullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6845-4453","authenticated-orcid":false,"given":"Vallentine Louzada","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-4695","authenticated-orcid":false,"given":"Aline Paim de Abreu Paulo","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Cesar","family":"Marcassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-4911","authenticated-orcid":false,"given":"Pablo Augustin","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4463-9602","authenticated-orcid":false,"given":"Ana Luiza Oliveira Corr\u00eaa","family":"Roza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0070-0640","authenticated-orcid":false,"given":"Andr\u00e9 Caroli","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-6617","authenticated-orcid":false,"given":"Alan Roger","family":"Santos-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0127-7998","authenticated-orcid":false,"given":"Ana Carolina","family":"Prado-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-6953","authenticated-orcid":false,"given":"Jo\u00e3o Gabriel Silva","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0442-0294","authenticated-orcid":false,"given":"Aljomar Jos\u00e9","family":"Vechiato-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"issue":"4","key":"key20260824165750_B1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.maturitas.2013.09.008","article-title":"Targeted cancer therapy\u2014are the days of systemic chemotherapy numbered?","volume":"76","author":"Joo","year":"2013","unstructured":"1 Joo WD, Visintin I, Mor G. Targeted cancer therapy\u2014are the days of systemic chemotherapy numbered? Maturitas. 2013;76(4):308-14.","journal-title":"Maturitas"},{"key":"key20260824165750_B2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails","volume":"19","author":"Lacouture","year":"2018","unstructured":"2 Lacouture M, Sibaud V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol. 2018;19(S1 Suppl 1):31-9.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"key20260824165750_B3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.oooo.2023.01.004","article-title":"Clinical characterization of stomatitis cases with an epithelial growth factor receptor inhibitor in metastatic colorectal cancer patients: A study of 7 cases and literature review","volume":"136","author":"Gomes-Silva","year":"2023","unstructured":"3 Gomes-Silva W, Vechiato-Filho AJ, Luiz AC, Guollo A, de Oliveira MC, Gomes MN, et al. Clinical characterization of stomatitis cases with an epithelial growth factor receptor inhibitor in metastatic colorectal cancer patients: A study of 7 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023;136(2):162-72.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"3","key":"key20260824165750_B4","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","unstructured":"4 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"key20260824165750_B5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11864-016-0434-0","article-title":"Cutaneous Complications of Targeted Melanoma Therapy","volume":"17","author":"de Golian","year":"2016","unstructured":"5 de Golian E, Kwong BY, Swetter SM, Pugliese SB. Cutaneous Complications of Targeted Melanoma Therapy. Curr Treat Options Oncol. 2016;17(11):57.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"key20260824165750_B6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","unstructured":"6 Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314-22.","journal-title":"Oncologist"},{"issue":"10","key":"key20260824165750_B7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","unstructured":"7 Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103-9.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"key20260824165750_B8","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdv390","article-title":"Alopecia in patients treated with molecularly targeted anticancer therapies","volume":"26","author":"Belum","year":"2015","unstructured":"8 Belum VR, Marulanda K, Ensslin C, Gorcey L, Parikh T, Wu S, et al. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol. 2015;26(12):2496-502.","journal-title":"Ann Oncol"},{"issue":"8","key":"key20260824165750_B9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","unstructured":"9 Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20260824165750_B10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","unstructured":"10 Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221-36.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"key20260824165750_B11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.12788\/j.sder.0061","article-title":"Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab","volume":"33","author":"Choi","year":"2014","unstructured":"11 Choi JN. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg. 2014;33(1):40-8.","journal-title":"Semin Cutan Med Surg"},{"issue":"6","key":"key20260824165750_B12","first-page":"2875","article-title":"Cost-effectiveness of photobiomodulation therapy for the prevention and management of cancer treatment toxicities: a systematic review","volume":"29","author":"Kauark-Fontes","year":"2021","unstructured":"12 Kauark-Fontes E, Rodrigues-Oliveira L, Epstein JB, Faria KM, Ara\u00fajo AL, Gueiros LA, et al. Cost-effectiveness of photobiomodulation therapy for the prevention and management of cancer treatment toxicities: a systematic review. Support Care Cancer. 2021;29(6):2875-84.","journal-title":"Support Care Cancer"},{"issue":"6","key":"key20260824165750_B13","first-page":"400","article-title":"Oral complications of cancer and cancer therapy: from cancer treatment to survivorship","volume":"62","author":"Epstein","year":"2012","unstructured":"13 Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400-22.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"key20260824165750_B14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cden.2013.12.005","article-title":"Chemotherapy or radiation-induced oral mucositis","volume":"58","author":"Lalla","year":"2014","unstructured":"14 Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am. 2014;58(2):341-9.","journal-title":"Dent Clin North Am"},{"issue":"6","key":"key20260824165750_B15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000499720","article-title":"Physical and Psychological Impairments Associated with Mucositis after Oral Cancer Treatment and Their Impact on Quality of Life","volume":"42","author":"Jehn","year":"2019","unstructured":"15 Jehn P Stier R, Tavassol F, Dittmann J, Zimmerer R, Gellrich NC, et al. Physical and Psychological Impairments Associated with Mucositis after Oral Cancer Treatment and Their Impact on Quality of Life. Oncol Res Treat. 2019;42(6):342-9.","journal-title":"Oncol Res Treat"},{"issue":"9","key":"key20260824165750_B16","first-page":"23","article-title":"Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes","volume":"5","author":"Rosenthal","year":"2007","unstructured":"16 Rosenthal DI. Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. J Support Oncol. 2007;5(9 Suppl 4):23-31.","journal-title":"J Support Oncol"},{"issue":"1","key":"key20260824165750_B17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"Sonis","year":"2010","unstructured":"17 Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116(1):210-5.","journal-title":"Cancer"},{"issue":"1-2","key":"key20260824165750_B18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/odi.12795","article-title":"Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients","volume":"24","author":"Lo Muzio","year":"2018","unstructured":"18 Lo Muzio L, Arena C, Troiano G, Villa A. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients. Oral Dis. 2018;24(1-2):144-71.","journal-title":"Oral Dis"},{"issue":"3","key":"key20260824165750_B19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/07357907.2014.1001893","article-title":"Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients","volume":"33","author":"Shameem","year":"2015","unstructured":"19 Shameem R, Lacouture M, Wu S. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Invest. 2015;33(3):70-7.","journal-title":"Cancer Invest"},{"issue":"6","key":"key20260824165750_B20","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/bjd.13610","article-title":"Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors","volume":"172","author":"Vigarios","year":"2015","unstructured":"20 Vigarios E, Lamant L, Delord JP, Fricain JC, Chevreau C, Barr\u00e9s B, et al. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors. Br J Dermatol. 2015;172(6):1680-2.","journal-title":"Br J Dermatol"},{"issue":"1","key":"key20260824165750_B21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/healthcare12010105","article-title":"Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review","volume":"12","author":"Basilicata","year":"2024","unstructured":"21 Basilicata M, Terrano V, D'Aurelio A, Bruno G, Troiani T, Bollero P et al. Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review. Healthcare (Basel). 2024;12(1):105.","journal-title":"Healthcare (Basel)"},{"key":"key20260824165750_B22","first-page":"3197","volume-title":"Principles and Practice of Ophthalmology","author":"Albert","year":"1994","unstructured":"22 Albert DM. Principles and Practice of Ophthalmology. In: Albert DM, Jakobiec FA, editors. Philadelphia (PA): W.B. Saunders Co; 1994. pp. 3197-8."},{"key":"key20260824165750_B23","first-page":"1","article-title":"Malignant melanoma of the uvea in Denmark 1943-1952, a clinical histopathological, and prognostic study","volume":"43","author":"Jensen","year":"1963","unstructured":"23 Jensen OA. Malignant melanoma of the uvea in Denmark 1943-1952, a clinical histopathological, and prognostic study. Acta Ophthalmol Suppl (Copenh). 1963;43 Suppl 75:1-220.","journal-title":"Acta Ophthalmol Suppl (Copenh)"},{"issue":"12","key":"key20260824165750_B24","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1200\/JCO.2004.08.194","article-title":"Collaborative Ocular Melanoma Study Group Report 23. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23","volume":"22","author":"Diener-West","year":"2004","unstructured":"24 Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Green DL, Hawkins BS, Hayman J, Jaiyesimi I, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Thoma J; Collaborative Ocular Melanoma Study Group Report 23. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004;22(12):2438-44.","journal-title":"J Clin Oncol"},{"issue":"1","key":"key20260824165750_B25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0974-620X.94718","article-title":"Choroidal melanoma","volume":"5","author":"Singh","year":"2012","unstructured":"25 Singh P, Singh A. Choroidal melanoma. Oman J Ophthalmol. 2012;5(1):3-9.","journal-title":"Oman J Ophthalmol"},{"issue":"10","key":"key20260824165750_B26","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","unstructured":"26 Sibaud V, Eid C, Belum VR, Combemale P, Barres B, Lamant L, et al. Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol. 2017;31(10):e464-9.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"18","key":"key20260824165750_B27","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","unstructured":"27 Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-703.","journal-title":"N Engl J Med"},{"issue":"26","key":"key20260824165750_B28","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","unstructured":"28 Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.","journal-title":"N Engl J Med"},{"issue":"20","key":"key20260824165750_B29","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","unstructured":"29 Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-76.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20260824165750_B30","first-page":"1713","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","unstructured":"30 Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25(5):1713-39.","journal-title":"Support Care Cancer"},{"issue":"2","key":"key20260824165750_B31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","unstructured":"31 Naranjo CA, Busto U, Sellers EM, Sandor P Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"key20260824165750_B32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","unstructured":"32 Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67(6):1265-72.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"key20260824165750_B33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0955-0674(97)80061-0","article-title":"Mitogen-activated protein kinase pathways","volume":"9","author":"Robinson","year":"1997","unstructured":"33 Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997;9(2):180-6.","journal-title":"Curr Opin Cell Biol"},{"issue":"8","key":"key20260824165750_B34","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","unstructured":"34 McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263-84.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"key20260824165750_B35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04546.x","article-title":"Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management","volume":"27","author":"Manousaridis","year":"2013","unstructured":"35 Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J. Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol. 2013;27(1):11-8.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"key20260824165750_B36","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","unstructured":"36 Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012;167(5):987-94.","journal-title":"Br J Dermatol"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:58:00Z","timestamp":1787590680000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/management-of-oral-stomatitis-associated-with-brafi-meki-therapy-using-intralesional-corticosteroid-and-local-anesthetic-a-case-report\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"journal-issue":{"issue":"spe3","published-print":{"date-parts":[[2026,8,21]]}},"alternative-id":["10.31744\/einstein_journal\/2026RC2409"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2026rc2409","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"eRC2409"}}